Can-Fite BioPharma (CANF)
XASE:CANF
Want to see CANF full AI Analyst Report?
CANF Stock Chart & Stats
$4.04
-$0.06(-3.61%)
At close: 4:00 PM EST
$4.04
-$0.06(-3.61%)
Day’s Range― - ―
52-Week Range$2.82 - $21.80
Previous CloseN/A
Volume35.97K
Average Volume (3M)258.05K
Market Cap
$6.47M
Enterprise Value$7.56B
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$90.00K
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 27, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding2,142,546
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.59
Price to Sales (P/S)8.07
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.17K
Enterprise Value/Revenue13.49K
Enterprise Value/Gross Profit13.49K
Enterprise Value/Ebitda-848.45
Forecast
1Y Price Target
$6.00Price Target Upside48.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageVery low leverage meaningfully reduces bankruptcy and refinancing risk for a clinical-stage biotech. A conservative capital structure preserves flexibility to fund trials or negotiate partnerships without immediate debt pressure, improving the company's ability to execute multi-stage development plans.
Clinical Progress For Namodenoson In Pancreatic CancerPositive Phase 2a safety and disease-stabilization signals, plus orphan designation, materially de-risk the program versus early-stage candidates. These durable clinical readouts underpin potential regulatory advantages, partnering interest, and a clearer path to larger combo trials and value creation in a high-unmet-need oncology market.
Vetbiolix Partnership And Veterinary Revenue PotentialA partner-funded veterinary program offloads development cost and shortens path to near-term revenue. The licensing structure with up to $325M upside diversifies revenue streams outside human therapeutics and reduces corporate cash burn while preserving upside if Piclidenoson succeeds commercially in companion animals.
Bears Say
Declining Revenue And Persistent Net LossesMaterial revenue contraction together with widening net losses signal limited commercial traction and ongoing negative economic returns. Persistent unprofitability constrains reinvestment into programs and elevates the likelihood of future equity raises or dilutive financings to sustain development cadence and operations.
Consistently Negative Cash Flow And Funding DependencyChronic negative operating and free cash flow create structural funding dependency. Even with occasional improvement, continued cash burn increases the company's reliance on external capital or partner milestones, making long-term program execution vulnerable to market conditions and potential dilution for shareholders.
Clinical-stage, Single-technology Pipeline ConcentrationAs a clinical-stage biotech with no marketed products, long-term value is binary and tied to trial outcomes and partner deals. Reliance on a small set of A3AR programs concentrates risk: failed readouts or slow enrollment materially delay or eliminate future revenues and make the firm dependent on successful external collaborations.
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $2.82 and its highest was $21.80 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $6.47M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Aug 27, 2026 which is in 65 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Mar 26, 2026. The company reported -$5.97 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$5.83.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Undervalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.51.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 2,142,546 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$5.97 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 1.858%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
CANF Stock 12 Month Forecast
Average Price Target
$6.00
▲(48.51% Upside)
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
1.99% Other Institutional Investors
98.01% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---